27 Apr ADA Statement Regarding Lilly’s Announcement of Weight Loss in Adults with Obesity and Type 2 Diabetes with Tirzepatide (Mounjaro™) Injections
Statement from Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA, regarding the Lilly statement this of April 27, 2023. The final results of this SURMOUNT-2 study will be announced at the ADA SciSessions in June, 2023. "Tirzepatide was effective at having people with diabetes lose 15.7 % of their...